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Translational researchIn vivo gene delivery has long been seen as providing opportunities for the development of novel treatments
for disorders refractory to existing therapies. Over the last two decades, salivary glands have proven to be a
useful, if somewhat unconventional, target tissue for studying several potential clinical applications of
therapeutic gene delivery. Herein, we follow the progress, address some problems and assess the outlook for
clinical applications of salivary gland gene delivery. Our experience with these tissues provides a roadmap for
the process of moving an idea from the laboratory bench to patients.g 10, Rm 1N113, MSC-1190,
+1 301 402 1228.
B.V.Published by Elsevier B.V.1. Introduction
The delivery of genes as a therapy for clinical disorders began in
earnest in the 1980s [e.g., 1,2]. Initially, and for many years thereafter,
investigations of clinical applications of gene delivery focused on
inherited disorders and on malignancies refractory to conventional
treatment. However, in the 1990s, many researchers began to explore
applying gene delivery to a wide range of conditions, including
acquired disorders, for which no suitable conventional therapy then
existed. Among the tissues examined at that time for potential clinical
applications were salivary glands [e.g., 3–7].
Although studies with salivary glands are relatively infrequent in
the modern translational research literature, these tissues have been
the subjects of classic studies in experimental medicine [8,9]. Thus, it
is perhaps not surprising that as a result of recent research, salivary
glands appear also to have many advantages for clinical gene delivery
(see Table 1). Most importantly, salivary glands are (i) easy to access
in a relatively non-invasive manner; (ii) well-encapsulated in
humans, which limits vector spreading; (iii) conﬁned targets, so
that the concentration of vector delivered is not diluted by other body
ﬂuids; (iv) easy tissues in which to assess several important
physiological processes; and (v) not necessary for life, if a severe
untoward complication were to develop. Furthermore, not only are
the two major clinical disorders affecting salivary glands (radiation
damage subsequent to treatment of head and neck cancers; Sjögren's
syndrome [10,11]) lacking adequate conventional therapy, but also
salivary glands are potentially useful for treating monoendocrinopa-
thies that currently do not have a suitable therapy [12,13].The latter application has not yet reached the clinic and, thus, is
not relevant to the primary focus of this review. However, it helps to
illustrate some of the existing difﬁculties with more general
applications of salivary gene transfer. Although exocrine glands, for
more than 50 years numerous reports have shown that salivary
glands also are able to secrete in an endocrine manner [e.g., 14–19].
Typically, salivary proteins are secreted via two principal pathways,
although additional, minor, subgroups exist: the major regulated
pathway and the constitutive pathway [20–22]. Regulated pathway
proteins are ﬁrst stored in secretory granules, where they await an
external stimulus for secretion. Thereafter, the cargo proteins in
granules are released into the forming saliva (unidirectional secre-
tion). In contrast, constitutive pathway proteins are secreted
continuously and non-directionally, roughly at the rate of their
translation. Proteins secreted via the constitutive pathway likely
account for endocrine secretion from salivary glands.
Over the last ~15 years we have studied the concept of employing
salivary glands as a surrogate endocrine organ using several model
human proteins, including α-1-antitrypsin (α1AT), erythropoietin
(Epo), growth hormone (GH) and parathyroid hormone (PTH)
[4,7,12,23,24]. While results with α1AT and GH have been relatively
straightforward, studies with Epo and PTH were not predictable, with
differences in their secretory behavior occurring between certain
species and gland types [e.g., 12,23–27]. Unfortunately, little is known
about the mechanisms responsible for the sorting of secretory
proteins in polarized epithelial cells. As a result, our aggregate studies
highlight the need to understand basic cellular mechanisms, in this
case secretory protein sorting, before salivary gene transfer for
treating monoendocrinopathies routinely can be exploited.
Research on gene delivery to salivary glands, using intraoral,
retroductal cannulation, has been performed by at least 16 separate
research groups worldwide (Table 2). Salivary gene delivery has been
Table 1
Advantages of salivary glands for clinical gene delivery.a
• The two major disorders affecting salivary glands (radiation damage; Sjögren's
syndrome) lack adequate conventional therapy
• There is an easy access of a gene transfer vector to almost all epithelial cells in a
gland via intraoral cannulation of the main excretory duct and infusion
• There is a readily deﬁned ﬂuid volume that can be infused into each gland
• The volume of infusate ﬂuid is not further diluted following vector delivery
• The luminal membrane of almost all epithelial cells in the gland is a potential
target for infused vectors
• Salivary epithelial cells divide slowly making a relatively stable target population
for non-integrating gene transfer vectors
• It is easy to measure neurotransmitter coupled secretory responses in salivary
glands (i.e., the gustatory stimulation of salivation)
• Salivary epithelial cells can produce signiﬁcant levels of transgenic proteins for
export in both exocrine and endocrine directions
• Human salivary glands are well-encapsulated minimizing the potential for vector
spread beyond the targeted gland
• If a severe and life-threatening adverse event were to occur, a single salivary gland
is not essential for life and could be readily removed
a Modiﬁed from Baum et al., Trends in Molecular Medicine, 2004 [83].
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prevention [30–32] of radiation damage, the treatment of Sjögren's
syndrome [33–35], and gene therapeutics (pharmacological applica-
tions) directed at both upper gastrointestinal tract [5,36] and systemic
[6,7,23,37] conditions. Additionally, salivary gland gene delivery has
been useful for asking biological questions in vivo [38–41], as well as
for creating novel models of disease [42,43]. While most of these
studies have been performed in rodent models (mice, rats), several
studies in large animal models have been reported (miniature pigs,
rhesus macaques [25,27,29,44,45]), and a human clinical trial
employing gene delivery to parotid glands is ongoing (see below;
[46]). Notably, as a result of detecting replication competent
adenovirus (Ad) in the saliva of one treated patient in this clinical
trial, the notion that vector spread beyond a targeted gland is limited
by the gland capsule, has been conﬁrmed [47]. The patient involved
apparently had a latent serotype 5 Ad (Ad5) infection in the targetedTable 2
Research groups that have shown applicability of salivary gland gene transfer.a
Radiation damage repair
• Baum et al., NIDCR, NIH, USA [28,29,71]
• Wang et al., Capital Medical University, PR China [29,71]
Prevention of radiation damage
• Baum et al., NIDCR, NIH, USA [31]
• Greenberger et al., University of Pittsburgh, USA [30]
• Sunvala-Dossabhoy et al., Louisiana State University, USA [32]
Treatment of Sjögren's syndrome
• Chiorini et al., NIDCR, NIH, USA [33]
• Tak et al., University of Amsterdam, The Netherlands [34,35]
Gene therapeutics (exocrine secretion)
• Baum et al., NIDCR, NIH, USA [5]
• Huang et al., University of California-Los Angeles, USA [36]
Gene therapeutics (endocrine secretion)
• Baum et al., NIDCR, NIH, USA [12,23]
• Passineau et al., Allegheny-Singer Research Institute, Pittsburgh, USA [37]
• Rothman et al., University of California-San Francisco, USA [6]
Physiology and pathophysiology
• Ambudkar et al., NIDCR, NIH, USA [38]
• Baum et al., NIDCR, NIH, USA [4,84]
• Kawaguchi et al., Tokyo Dental College, Japan [41]
• Kulkarni et al., NIDCR, NIH, USA [43]
• Weigert et al., NIDCR, NIH, USA [40]
General gene transfer
• Barka et al., City University of New York, USA [85]
• Bennett et al., Genteric, Inc, USA [86]
• Chiorini et al., NIDCR, NIH, USA [39]
• Palmon et al., Hebrew University, Israel [87]
• Passineau et al., Allegheny-Singer Research Institute, Pittsburgh, USA [88]
a Only senior authors are mentioned for space considerations, with our apologies to
the other authors. See [References] for the appropriate citations.gland, which was activated following vector delivery. The conse-
quently ampliﬁed vector and wild type Ad5 were only found in
parotid saliva from the targeted gland, with neither ever detected,
using sensitive real time-quantitative PCR assays, in the patient's
serum [47].
It is the purpose of this review to use some of our group's
experiences to illustrate the process of translating biological science
advances from the bench into the clinic.
2. Biotechnology
2.1. Overview of the process
The steps required for moving all potential clinical treatments
from the bench to the clinic are multiple, and vary somewhat
depending upon the nature of the treatment being considered, e.g., for
a gene, a recombinant protein or a traditional type of pharmaceutical.
Table 3 provides a fairly detailed listing of the key steps that were
involved in moving a gene delivery strategy for repairing radiation
damage to salivary glands from a general idea into a clinical trial now
being conducted at the US National Institutes of Health-Clinical
Research Center ([46]; clinical protocol 06-D-0206; see Section 3,
below). This study involves using a recombinant Ad5 vector encoding
the archetypal water channel protein, human aquaporin-1 (hAQP1
[48]; AdhAQP1) for the treatment of a single parotid gland in patients
who have received radiation therapy for the treatment of a squamous
cell carcinoma in the head and neck region. To go from the ﬁrst step
(identiﬁcation of the problem) to the last step (initiating patient
enrollment in this study) took us 16 years. This is a fairly long time,
albeit not unusual, and required considerable and stable institutional
support.
At the time the idea of a potential gene therapy for salivary gland
radiation damage was crystallized, we had none of the knowledge,
skills or experience required to work with recombinant viral vectors,
though we were well versed in salivary gland biology. It took three
years for us simply to demonstrate the feasibility of salivary gland
gene transfer using an Ad5 vector and intraductal cannulation [3], and
an additional three years to show efﬁcacy in the ﬁrst animal model
(rat) tested [28]. For developing clinical applications of gene delivery,
and other types of biological therapies, it is essential to show scalingTable 3
Steps in taking a potential gene therapy from the bench to the clinic.a
• Identiﬁcation of a clinical problem without conventional therapy
• Development of the therapeutic idea using gene transfer
• Understanding the biology of the intended target tissue
• Assessment of the risk/beneﬁt ratio for using viral and non-viral vectors
• Decision on the vector to be used (herein, a viral vector)
• Understanding the biology of the vector to be used
• Determining the availability of suitable in vitro and in vivo (small and large
animal) models for testing the idea
• Construction of the vector to be used
• Functional testing of the vector in vitro
• Efﬁcacy studies with the vector in a small animal disease model
• Efﬁcacy studies with the vector in a large animal disease model
• Conducting a toxicology and biodistribution study with the vector in small
animals (GLP levelb)
• Development of a clinical protocol
• Required reviews and approval of the clinical protocolc
• Production of a clinical grade gene transfer vector (GMPd)
• Establishment of the infrastructure required to support the study
• Patient enrollment
a Modiﬁed from Baum et al., Oral Oncology, 2010 [46].
b GLP, Good Laboratory Practice as deﬁned by the US Food and Drug Administration.
c For the AdhAQP1 clinical study discussed herein, ﬁve separate reviews were
required: NIDCR Institutional Review Board, NIH Biosafety Committee, US Recombinant
DNA Advisory Committee, US Food and Drug Administration, and the study's Data
Safety and Monitoring Board.
d GMP, Good Manufacturing Practice as deﬁned by the US Food and Drug
Administration.
Fig. 1. Administration of gene transfer vectors to an animal and a patient.
(a) Photograph of rat with both submandibular glands cannulated through the oriﬁces
of Wharton's duct in the ﬂoor of the mouth. Each cannula is connected to a syringe
(bottom right and left of the ﬁgure), through which a gene transfer vector is being
infused. Animals undergoing salivary gland gene transfer are anesthetized only for
restraint. (b) Photograph of a patient in NIH clinical protocol 06-D-0206 who has the
left parotid gland cannulated through Stensen's duct in the buccal mucosa and is
receiving the AdhAQP1 vector through a syringe attached to the cannula.
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(8 years), as we initially tried to conduct a study in rhesus macaques
[50], but found it much too expensive to test appropriate numbers of
animals. We then switched to a miniature pig model [44,51], and
eventually showed efﬁcacy in a study using a fairly large number of
animals (n=18, [29]).
The actual process of protocol development and approval took
about 3 years. This included reviews by ﬁve separate groups: the
NIDCR Institutional Review Board (IRB), the US Recombinant DNA
Advisory Committee (RAC), the NIH Biosafety Committee, the US Food
and Drug Administration (FDA), and the study's Data Safety and
Monitoring Board (DSMB). We were quite fortunate to have used two
consultants to help with shaping the ﬁnal clinical protocol and the
Investigational New Drug (IND) application to the FDA. Both
individuals, one a PhD molecular biologist and the other a physician,
had considerable prior work experience at the FDA and, thus, were
able to provide us with both tangible guidance in required procedures,
as well as a perspective on the entire process. As a result of their
guidance, the protocol and IND applications were well prepared, and
the review and approval process proceeded in a timely manner. The
time from the initial submission to the IRB, until the ﬁnal approval of
the DSMB permitting us to commence enrolling patients, was
~18 months, including a public review of the protocol by the RAC.
Each of the ﬁve groups involved in the approval process was thorough
and made inquiries consistent with their responsibilities and the
nature of the protocol. Given that this protocol was the ﬁrst gene
therapy proposed for a salivary gland, designed to treat a condition
affecting quality of life, albeit one without any existing treatment, to
us the entire process seemed fair, constructive and appropriate.
The production of the clinical grade AdhAQP1 vector and
establishment of the required infrastructure, most notably developing
an electronic database containing all required case report forms and
creating a study monitoring system, was begun during the latter
stages of the review and approval process and was completed
~10 months after all approvals were obtained. Although our institute
had minimal infrastructure for conducting a study of this type, it
provided us with an experienced Contract Research Organization
(CRO) to establish what was needed. Similarly to our positive
experience with the protocol and IND application consultants, we
beneﬁted greatly from working with a CRO that knew what was
required to ensure that the AdhAQP1 study was conducted safely and
efﬁciently. In hindsight, we probably should have begun the
infrastructure development process sooner, as absent proper infra-
structure patient enrollment was delayed signiﬁcantly. However, we
chose to proceed cautiously and waited until late in the approval
sequence before commencing.
2.2. Method of gene delivery to salivary glands
Clinical gene delivery to major salivary glands (parotid and
submandibular) can be considered a minimally invasive procedure.
The technique, which requires no local anesthesia, is based on
cannulation of Stensen's (parotid) or Wharton's (submandibular)
ducts, which are readily accessible in the mouth. In fact, such
cannulation is routinely used in taking contrast x-rays (sialography)
of the glands [52]. During the procedure, the duct oriﬁce is ﬁrst
identiﬁed (surgical magniﬁcation loops are useful), and then probed
to allow access and cannulation with a blunt-ended catheter (Fig. 1).
Introduction of the vector (or contrast agent in the case of
sialography) is performed typically by hand injection, but could also
be performed using a continuous-infusion pressure-monitored tech-
nique. In humans, the hydrostatic pressure allows the infusion of an
average 0.5–1.5 ml volume (determined exactly for each patient), and
prevents overﬁlling of the gland and reduces discomfort [53].
Gene delivery to salivary glands of animals is performed in a
similar fashion, although anesthesia is used only for restraint. Thecannulation of salivary ducts in rodents requires the use of a
stereomicroscope and small catheters. In fact, we routinely prepare
catheters by stretching polyethylene PE-10 tubing over an open ﬂame,
thinning them to the appropriate diameter. To prevent back-ﬂow of
the infusate following its administration in animals, we use
cyanoacrylate to temporarily adhere the catheter to the duct opening
(Fig. 1a; rat submandibular gland is cannulated). Vector volume is
important for attaining maximal transgene expression. The optimal
volume varies by species and is 50 and 200 μl for mouse and rat
submandibular glands, respectively [54,55], 500 μl for the parotid
glands of rhesus macaques [45], and 4000 μl for a miniature pig
parotid gland [44].
2.3. Principal vectors used for salivary gene transfer
Transfer of genes into cells can be accomplished using viral and
non-viral vectors. Currently, viral vectors provide the most efﬁcient
means for gene transfer, but they raise safety concerns including, in
particular, the risk of insertional mutagenesis and the possibility that
their manufacture or use will generate replication-competent viruses.
Additionally, viral vectors can elicit immune responses, which can be
marked and prevent the repeated use of the product [56–58]. In
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safety risk, but is inefﬁcient in transducing mammalian cells. Methods
for non-viral gene delivery use physical and chemical approaches to
improve efﬁcacy and cell speciﬁcity. Direct injection, a gene gun,
electroporation, sonoporation (microbubbles) and laser irradiation have
all been studied as physical means to improve gene transfer [59–63].
Chemical approaches aim to enhance endosomal escape, intracellular
trafﬁcking and nuclear import of the transferred gene and use
cationic liposomes or polymers most frequently [64]. For salivary
glands, non-viral vectors are seldom employed, while Ad5 or
serotype-2 adeno-associated viral (AAV2) vectors are most often
used.
By 2009, over 350 protocols (including NIH # 06-D-0206; see
below) using Ad5 vectors have been approved for clinical trials. Ad5
vectors are also extremely useful in proving a concept for potential
clinical application. They readily transduce salivary gland epithelial
cells in animals (mice, rats, miniature pigs, and non-human primates)
and produce a high level of expression of the delivered gene, albeit
transiently (typically 7–14 days [65]), because of a considerable
immune response. In comparison, AAV2 vectors induce substantially
less host immune reactivity and thus AAV2-mediated transgene
expression lasts much longer [45]. Although AAV2 vectors are more
difﬁcult to construct, in great part because their biology is less
understood than that of Ad5, AAV2 vectors are quite useful in studies
that require long-term expression. Importantly, wild type AAV2 is not
associated with any known pathology in humans.
3. AdhAQP1 to correct radiation-induced parotid hypofunction
Salivary glands are composed of two distinct major cell types:
acinar cells and duct cells (Fig. 2). Acinar cells are water-permeable
and NaCl secreting, i.e., an acinus is a secretory epithelium. Acinar cells
are considered to be the only site of ﬂuid movement in these glands,
and generate an isotonic, so-called “primary” ﬂuid [66,67]. Duct cells
are essentially water-impermeable and reabsorb considerable NaCl
making the ﬁnal secreted saliva markedly hypotonic, i.e., the salivary
duct system behaves as an absorptive epithelium. Radiation used in
the treatment of head and neck cancers leads to the loss of acinar cells
in the radiation ﬁeld, which is likely a result of several targeted insults
[10]. Consequently, damaged salivary glands in surviving head and
neck cancer patients have predominantly duct cells remaining, i.e.,
unable to secrete ﬂuid, and the patients experience signiﬁcant salivary
hypofunction, often termed xerostomia (dry mouth). With a ﬁve-year
survival rate of ~60%, such patients (Radiation Therapy Oncology
Group categories 2 and 3, [68]) suffer from dysphagia, frequent oral
infections, poor oral mucosal wound healing and a marked reduction
in quality of life [69,70], and there is no adequate conventional
therapy available.
As depicted in Fig. 2, we posited that, in the absence of signiﬁcant
acinar cell primary ﬂuid formation, duct cells were capable of
generating a lumenN interstium osmotic gradient [28,46]. This
conjecture, based on limited published data obtained using rodent
models, assumed the formation of a KHCO3−-driven osmotic gradientFig. 2. Schematic depiction of the gene transfer strategy being employed in the A
This ﬁgure was originally published in Oral Oncology [46] and is reprinted with[discussed in 28,29,71], but the exact mechanism remains unproven.
However, in order to achieve actual ﬂuid secretion, whatever the
nature of the osmotic gradient, water would be unable to follow since
duct cells lacked facilitated water permeability pathways (water
channels) in their plasmamembranes. Serendipitously, at the timewe
were developing our ideas, Preston and Agre published a report
describing the isolation of the cDNA for hAQP1 [48]. Thus, we
hypothesized that delivering the hAQP1 cDNA to duct cells in
radiation-damaged salivary glands could lead to ﬂuid secretion by
providing facilitated water permeability pathways in these cells. This
hypothesis was tested initially using the AdhAQP1 vector to transduce
cells in irradiated rat submandibular glands [28]. Under the optimal
conditions employed, this maneuver resulted in near normal salivary
ﬂow rates in the irradiated animals, while a control Ad5 vector was
without beneﬁt [28].
Thereafter, as noted above, we decided to test the same hypothesis
in a large animal model, targeting the parotid glands of rhesus
macaques. This model was chosen because of (i) its obviously close
relationship to humans and (ii) past experiences studying parotid
saliva secretion in this species [e.g., 72,73]. We were able to obtain
ﬁve, male, out-bred rhesus macaques (~8–10 kg each) for study and
decided to use two animals in each of two AdhAQP1 dosage groups
with one animal to receive an Ad5 control vector [50]. In retrospect,
this was an ill-advised experimental design, as the small number of
animals could not accommodate normal variations in salivary
secretion, as well as variability in radiation damage, and the ﬁnal
results were equivocal [50].
We decided, next, to repeat the AdhAQP1 rat study, and obtained
results generally comparable to those of our original study [74]. With
that impetus, we then re-explored possible large animal models to
use. An important consideration was that the model would be more
affordable and less labor intensive for us to manage. We decided to
use miniature pigs, collaborating with a research group in China.
These animals are much larger thanmacaques (~25–30 kg), markedly
less expensive, and it had been shown previously by our collaborators
that their parotid glands were in many ways similar to those of
humans [51]. Using an Ad5 vector encoding the luciferase reporter
gene, we demonstrated good dose scaling between mice and
miniature pigs [44], as well as signiﬁcantly greater radiation
sensitivity than that of rats [75,76]. Accordingly, we then tested our
original hypothesis in miniature pigs whose parotid glands had been
subjected to radiation. We obtained similar results to those found in
the rat studies (Fig. 3, [29]), using three separate cohorts of miniature
pigs and, in fact, much lower doses of the AdhAQP1 vector.
All of our studies in rats, rhesus macaques and miniature pigs also
had suggested that delivery of an Ad5 vector to the salivary glands
was generally safe. However, in order to consider a possible clinical
trial, we needed to conduct detailed safety studies, monitoring
potential toxicological responses, as well as vector bio-distribution,
after salivary gland delivery. As indicated in Table 3, we also had to
conduct this study under the Good Laboratory Practice (GLP)
guidelines established by the US FDA. These studies, using 100 male
and 100 female rats, were conducted in collaboration with colleaguesdhAQP1 clinical trial (NIH clinical protocol 06-D-0206). See text for details.
permission.
Fig. 3. Results from the key preclinical efﬁcacy test of the AdhAQP1 gene transfer strategy shown in Fig. 2. The parotid glands of miniature pigs were irradiated at time zero and after
16 weeks parotid salivary ﬂow (normalized to 100%) was reduced by ~80%. At week 17, animals were given the AdhAQP1 vector, or a control vector encoding luciferase, in the
irradiated glands. Parotid salivary ﬂow increased promptly thereafter in the AdhAQP1-treated glands. See text for additional details.
This ﬁgure was originally published in Molecular Therapy [29] and is reprinted with permission.
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group, administered the buffer diluent, three doses of AdhAQP1,
which we thought would span the dose range expected for use in a
clinical trial, were tested. The results were similar to those observed in
our non-GLP studies, i.e., delivery of AdhAQP1 to a salivary gland was
essentially safe and vector was primarily contained within the
targeted gland [77].
Thereafter, based on the small and large animal efﬁcacy studies,
and the rat safety study, we began to develop a clinical protocol,
which received all ﬁve required approvals, and concurrently arranged
for the clinical grade vector to be produced by the Belfer Gene Therapy
Core Facility at Weill Medical College of Cornell University (New York,
NY). More detailed information about the approved protocol, “Open-
label, dose-escalation study evaluating the safety of a single
administration of an adenoviral vector encoding human aquaporin-
1 to one parotid salivary gland in individuals with irradiation-induced
parotid salivary hypofunction” (NIH # 06-D-0206), can be found at
the Clinicaltrials.gov web site (http://www.clinicaltrials.gov/ct/show/
NCT00372320?order=) and at the study web site (http://www.
drymouthstudy.com/), as well as in a previous, brief review [46].
Fifteen patients were approved for treatment under this protocol, in
ﬁve dosage groups, from 4.8×107 to 3.5×1010 vector particles/gland.
Eleven patients have been treated as of this date (June 21, 2011), and
all patients have tolerated the vector and study procedures well.
Formal analysis of the efﬁcacy data has not yet been performed, and
reports of the safety and efﬁcacy data will be submitted separately for
publication following study completion.
4. Conclusions
There is now a considerable body of published literature to
demonstrate the feasibility of using gene delivery to salivary glands
for clinical applications. While to date, there is only a single approved
clinical trial employing salivary gland gene delivery, already some key
advantages of targeting this tissue have been conﬁrmed in patients. As
in all animal models, not surprisingly, there is an easy access and
delivery of patient-speciﬁc volumes of vector to the targeted glands,
and vector also appears to be well contained within the gland.
The rate of progress in translating basic and pre-clinical research
into clinical applications for gene delivery to salivary glands, however,
has been modest. In part, this is certainly a reﬂection of progress
generally in the gene therapy ﬁeld [78], as well as the general nature
of conducting bench to clinic studies [79,80]. Additionally, although
many research groups have demonstrated feasibility (Table 2), thenumber of investigators actively pursuing clinical applications of
salivary gland gene delivery is relatively small; as far as we know, only
six of the research groups listed in Table 2. This relative paucity of
investigators obviously also affects rates of progress. Furthermore,
this already limited number is coupled with a relatively small number
of investigators who study fundamental questions about the biology
of salivary glands, also hindering bench to clinic progress with this
tissue. An excellent example of the latter, discussed above, relates to
the problem of understanding signals that differentiate secretory
protein sorting to the regulated versus constitutive pathways, i.e.,
exocrine versus endocrine secretion. An understanding of this
fundamental biological issue is needed before full advantage of
using salivary glands as a target tissue for systemic gene therapeutics
can be achieved [81].
Nonetheless, there are real and valuable translational possibilities
available through salivary gene delivery. The process of moving
science between the bench and the clinic is complex and generally
slow [82], and is ﬁlled with many “bumps in the road” [82]. However,
it is achievable, as we hope has been demonstrated herein.Acknowledgment
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